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Sir,
We would like to make comment on the above article, which as
its main conclusion found that abnormal p53 was associated with
failure of response to radiotherapy in patients with rectal cancer.
Our department has recently conducted a similar analysis focusing
purely on rectal cancer undergoing neoadjuvant treatment and the
conclusions that we drew were somewhat different.
In total, we sourced 22 studies that assessed p53 status in this
setting. Of these, 18 used immunohistochemistry (IHC) and only four
(18%) showed that it could predict response. A further six studies
assessed the p53 gene directly, four using single-strand conforma-
tional polymorphism analysis (ssCP) (Sakakura et al, 1998; Elsaleh
et al, 2000; Rau et al, 2003; Saw et al, 2003) and two using direct p53
gene sequencing (DGS) (Kandioler et al, 2002; Rebischung et al,
2002). No study (0%) where ssCP was used could predict response.
While both the studies where DGS was used showed that tumours
manifesting mutations in p53 were less likely to respond, we feel that
these results should be interpreted with caution for several reasons.
Firstly, patients in both DGS studies underwent short-course
radiotherapy, whereas there is an increasing use of long-course
neoadjuvant radiochemotherapy (RCT) as standard of care in
many institutions (Sauer et al, 2004). Also, the pathological end
point used in both studies was a decrease in T stage determined
by comparison of pretreatment transrectal ultrasound (TRUS) and
postoperative pathological staging, which may be unreliable. For
example, a recently published study of 1184 patients undergoing
pretreatment staging by TRUS found that it had an overall staging
accuracy of 69% due to its limited depth of acoustic penetration
preventing accurate staging of locally advanced tumours (Garcia-
Aguilar et al, 2002). In addition, specific analyses of tumours that
have undergone a decrease in T stage post-RCT showed that up to
41% of these may harbour residual tumour deposits in the lymph
nodes (Medich et al, 2001; Zmora et al, 2004).
We therefore feel that the conclusion of this study, based
principally on the results of two papers, is a little premature. What
does seem apparent, however, is that IHC and ssCP analysis of p53
yield unreliable and heterogeneous results. While DGS may hold
promise, the question of whether such an expensive and labour-
intensive technique will become useful in the clinical setting still
remains to be answered.
REFERENCES
Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B
(2000) Can p53 alterations be used to predict tumour response to pre-
operative chemo-radiotherapy in locally advanced rectal cancer? Radio-
ther Oncol 56: 239
Garcia-Aguilar J, Pollack J, Lee SH, Hernandez de Anda E, Mellgren A,
Wong WD, Finne CO, Rothenberger DA, Madoff RD (2002) Accuracy of
endorectal ultrasonography in preoperative staging of rectal tumors. Dis
Colon Rectum 45: 10
Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F,
Kuhrer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann
M, Karner-Hanusch J, Potter R, Jakesz R, Teleky B, Herbst F (2002) TP53
genotype but not p53 immunohistochemical result predicts response to
preoperative short-term radiotherapy in rectal cancer. Ann Surg 235: 493
Medich D, McGinty J, Parda D, Karlovits S, Davis C, Caushaj P, Lembersky
B (2001) Preoperative chemoradiotherapy and radical surgery for locally
advanced distal rectal adenocarcinoma: pathological findings and clinical
implications. Dis Colon rectum 44: 1123
Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess
H, Schlag PM, Dorken B, Daniel PT (2003) Dynamic expression profile of
p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated
with preoperative radiochemotherapy. J Clin Oncol 21: 3391
Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P
(2002) Prognostic value of P53 mutations in rectal carcinoma. Int J
Cancer 100: 131
Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, Kimura A, Taniguchi
H, Hagiwara A, Yamaguchi T, Inazawa J, Abe T, Takahashi T, Otsuji E
(1998) Analysis of histological therapeutic effect, apoptosis rate and p53
status after combined treatment with radiation, hyperthermia and 5-
fluorouracil suppositories for advanced rectal cancers. Br J Cancer 77: 159
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R,
Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T,
Schmidberger H, Raab R (2004) Preoperative versus postoperative
chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731
Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S,
Chapuis P, Solomon MJ (2003) p53, deleted in colorectal cancer gene,
and thymidylate synthase as predictors of histopathologic response and
survival in low, locally advanced rectal cancer treated with preoperative
adjuvant therapy. Dis Colon Rectum 46: 192
Zmora O, Dasilva GM, Gurland B, Pfeffer R, Koller M, Nogueras JJ, Wexner
SD (2004) Does rectal wall tumor eradication with preoperative
chemoradiation permit a change in the operative strategy? Dis Colon
Rectum 47: 1607
*Correspondence: Dr FM Smith; E-mail: fassiefern@hotmail.com
Published online 26 April 2005
British Journal of Cancer (2005) 92, 1813
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com